Kelly K. Filipski, Ph.D., M.P.H.
Program Director, Clinical and Translational Epidemiology Branch
- Telephone: (240) 276-6841
- Fax: (240) 276-7920
- E-mail: firstname.lastname@example.org
Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
9609 Medical Center Drive, Rm. 4E228, MSC 9763
Bethesda, MD 20892
(For express delivery, use Rockville, MD 20850)
- Pharmacogenomic factors related to cancer treatment outcomes and toxicity
- Ph.D. - Integrated Program in Biomedical Sciences, Molecular Therapeutics and Cell Signaling
The University of Tennessee Health Science Center
Johns Hopkins University, Bloomberg School of Public Health
- B.S. - Biology and Psychology
Dr. Kelly Filipski is a Program Director in the Clinical and Translational Epidemiology Branch (CTEB). She is responsible for developing and managing a research grant portfolio focused on the pharmacogenomics of cancer treatment outcomes and toxicity.
Prior to joining EGRP, Dr. Filipski was a NCI Cancer Prevention Fellow in the U.S. Food and Drug Administration's Office of Clinical Pharmacology. As a Fellow, she conducted research focused on predictive biomarkers of cancer treatment and on labeling recommendations for approved drugs with biomarker information.
During her time at The University of Tennessee Health Science Center, Dr. Filipski served as a graduate research assistant in the Department of Pharmaceutical Sciences at St. Jude Children's Research Hospital. She conducted laboratory research focused on drug induced nephrotoxity and genomic variability in drug transporter proteins, resulting in the receipt of two honors, the Presidential Trainee Award and the Jason Morrow Trainee Award, from the American Society for Clinical Pharmacology and Therapeutics.